Physician profile
Georges Azzi
NPI 1265743017
$117,975.68
in general payments reported to CMS, 2019-2025
80 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,609 · 2020: $630 · 2021: $12K · 2022: $9,963 · 2023: $46K · 2024: $24K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $14K · Travel and Lodging: $5,885 · Long Term Medical Supply Or Device Loan: $2,250 · Education: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,648.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,236.25 |
| Food and Beverage | $13,572.35 |
| Travel and Lodging | $5,885.21 |
| Long Term Medical Supply Or Device Loan | $2,249.91 |
| Education | $434.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $49,894.68 | 2021-2025 | Clonoseq |
| Astellas Pharma US INC | $16,420.40 | 2020-2025 | Padcev, Xospata, Xtandi |
| Pfizer INC. | $5,700.13 | 2019-2025 | |
| Gilead Sciences, INC. | $4,706.66 | 2019-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $4,683.40 | 2019-2025 | Kisqali, Piqray |
| Seagen INC. | $4,597.55 | 2019-2023 | Padcev, Adcetris, Tivdak |
| Exelixis INC. | $3,826.99 | 2021-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $3,779.55 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Astellas Pharma Global Development | $3,696.74 | 2021-2024 | Padcev |
| Astrazeneca Pharmaceuticals Lp | $3,253.74 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Avyxa Pharma, LLC | $2,580.62 | 2025 | |
| Kite Pharma, INC. | $1,690.00 | 2021 | |
| Janssen Biotech, INC. | $1,521.58 | 2019-2025 | Erleada, Darzalex, Talvey |
| Tempus Ai, INC | $1,332.43 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $1,028.97 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $872.53 | 2019-2025 | Tecentriq, Alecensa, Venclexta |
| Lilly USA, LLC | $563.31 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $526.34 | 2019-2025 | Reblozyl, Pomalyst |
| Puma Biotechnology, INC. | $465.74 | 2019-2025 | Nerlynx |
| Glaxosmithkline, LLC. | $459.06 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Abbvie INC. | $442.41 | 2019-2025 | Venclexta |
| Array Biopharma INC | $430.94 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $387.27 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Incyte Corporation | $377.91 | 2021-2025 | Jakafi |
| Daiichi Sankyo INC. | $346.49 | 2020-2025 | Enhertu, Datroway |
| Eisai INC. | $335.08 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $261.81 | 2021-2025 | Qinlock, Tgct, Romvimza |
| Alexion Pharmaceuticals, INC. | $254.48 | 2023-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $245.58 | 2023-2024 | Krazati |
| Amgen INC. | $244.97 | 2019-2023 | Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $231.39 | 2021-2025 | |
| Tersera Therapeutics LLC | $225.80 | 2022-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $221.47 | 2021-2025 | Onivyde, Somatuline Depot |
| Pharmaessentia USA Corporation | $157.28 | 2022-2025 | Besremi |
| Janssen Pharmaceuticals, INC | $155.41 | 2020-2025 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.29 | 2019-2025 | |
| Taiho Oncology, INC. | $114.82 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $105.45 | 2020-2024 | Xpovio |
| Rigel Pharmaceuticals, INC. | $99.90 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Blue Earth Diagnostics | $94.85 | 2022-2024 | |
| Emd Serono, INC. | $92.94 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $92.70 | 2024 | Sylvant |
| Stemline Therapeutics INC. | $90.93 | 2025 | Orserdu |
| Adc Therapeutics America, INC. | $83.55 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $81.89 | 2023-2025 | Empaveli |
| Dova Pharmaceuticals | $77.88 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $70.55 | 2021-2025 | |
| Sobi, INC | $67.41 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $64.25 | 2019-2022 | |
| Blueprint Medicines Corporation | $59.46 | 2021-2022 | |
| Legend Biotech USA INC. | $59.40 | 2024 | |
| Genzyme Corporation | $51.43 | 2021-2024 | |
| Kyowa Kirin, INC. | $46.21 | 2021-2024 | Poteligeo |
| Foundation Medicine, INC. | $43.34 | 2020-2022 | |
| Immunogen, INC. | $41.14 | 2023 | Elahere |
| Janssen Scientific Affairs, LLC | $38.85 | 2019-2025 | Erleada, Balversa, Rybrevant |
| Sun Pharmaceutical Industries INC. | $35.28 | 2022-2024 | |
| Advanced Accelerator Applications | $30.20 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $29.99 | 2025 | Stimufend |
| Intuitive Surgical, INC. | $29.61 | 2023 | Da Vinci Surgical System |
| Sumitomo Pharma America, INC. | $29.55 | 2024 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $29.50 | 2025 | Libtayo |
| Acrotech Biopharma INC. | $26.71 | 2024 | Ryzneuta |
| Agios Pharmaceuticals, INC. | $23.98 | 2023 | Pyrukynd |
| Accord Healthcare, INC. | $20.79 | 2023 | |
| Myovant Sciences INC. | $20.62 | 2021 | |
| Syndax Pharmaceuticals, INC. | $20.20 | 2025 | |
| Fennec Pharmaceuticals, INC. | $20.20 | 2024 | Pedmark |
| Cti Biopharma Corp. | $19.49 | 2023 | Vonjo |
| Csl Behring | $19.47 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $18.72 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.29 | 2024 | Cosela |
| Mylan Institutional INC. | $16.59 | 2021 | |
| Genmab U.S., INC. | $16.43 | 2024 | Epkinly |
| G1 Therapeutics, INC. | $14.54 | 2023 | Cosela |
| Myriad Genetic Laboratories, INC. | $13.06 | 2021 | |
| Organon LLC | $10.51 | 2022-2023 | Ontruzant |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georges Azzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.